11,342 Shares in Guardant Health, Inc. (NASDAQ:GH) Bought by Cibc World Markets Corp

Cibc World Markets Corp bought a new stake in Guardant Health, Inc. (NASDAQ:GH - Free Report) in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm bought 11,342 shares of the company's stock, valued at approximately $346,000.

Several other institutional investors also recently made changes to their positions in the stock. Wellington Management Group LLP increased its stake in shares of Guardant Health by 188.6% during the 3rd quarter. Wellington Management Group LLP now owns 10,127,528 shares of the company's stock worth $232,325,000 after purchasing an additional 6,618,785 shares in the last quarter. Eventide Asset Management LLC boosted its position in Guardant Health by 2.0% during the third quarter. Eventide Asset Management LLC now owns 3,837,300 shares of the company's stock worth $88,028,000 after acquiring an additional 76,762 shares during the last quarter. Geode Capital Management LLC grew its stake in Guardant Health by 1.1% in the 3rd quarter. Geode Capital Management LLC now owns 2,822,220 shares of the company's stock worth $64,754,000 after acquiring an additional 29,686 shares during the period. Sumitomo Mitsui Trust Group Inc. lifted its stake in shares of Guardant Health by 19.4% during the 4th quarter. Sumitomo Mitsui Trust Group Inc. now owns 1,464,213 shares of the company's stock worth $44,732,000 after purchasing an additional 238,037 shares during the period. Finally, Two Sigma Advisers LP boosted its holdings in shares of Guardant Health by 52.7% during the third quarter. Two Sigma Advisers LP now owns 1,177,300 shares of the company's stock worth $27,007,000 after purchasing an additional 406,500 shares during the last quarter. 92.60% of the stock is currently owned by hedge funds and other institutional investors.

Remove Ads

Guardant Health Stock Performance

Shares of GH traded down $2.01 during mid-day trading on Friday, reaching $43.14. 1,168,890 shares of the company's stock traded hands, compared to its average volume of 2,180,890. Guardant Health, Inc. has a 12 month low of $15.81 and a 12 month high of $50.89. The stock has a market capitalization of $5.32 billion, a P/E ratio of -12.12 and a beta of 1.50. The business's 50-day moving average price is $44.66 and its 200-day moving average price is $34.24.

Guardant Health (NASDAQ:GH - Get Free Report) last released its earnings results on Thursday, February 20th. The company reported ($0.90) earnings per share for the quarter, missing analysts' consensus estimates of ($0.75) by ($0.15). Guardant Health had a negative return on equity of 19,157.20% and a negative net margin of 59.05%. The firm had revenue of $201.81 million during the quarter, compared to analyst estimates of $192.50 million. Equities research analysts anticipate that Guardant Health, Inc. will post -2.9 EPS for the current year.

Analyst Upgrades and Downgrades

A number of research firms recently issued reports on GH. Canaccord Genuity Group boosted their target price on shares of Guardant Health from $42.00 to $60.00 and gave the company a "buy" rating in a report on Monday, February 24th. Morgan Stanley boosted their target price on Guardant Health from $42.00 to $52.00 and gave the stock an "overweight" rating in a report on Thursday, March 6th. Barclays started coverage on shares of Guardant Health in a report on Thursday, January 23rd. They issued an "overweight" rating and a $60.00 price target on the stock. JPMorgan Chase & Co. boosted their price objective on shares of Guardant Health from $50.00 to $55.00 and gave the stock an "overweight" rating in a research note on Friday, February 21st. Finally, The Goldman Sachs Group raised their target price on shares of Guardant Health from $49.00 to $56.00 and gave the company a "buy" rating in a research note on Friday, February 21st. Twenty investment analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, the stock currently has a consensus rating of "Buy" and an average price target of $48.95.

About Guardant Health

Guardant Health, Inc, a precision oncology company, provides blood and tissue tests, data sets, and analytics in the United States and internationally. The company provides Guardant360; Guardant360 LDT; Guardant360 CDx Test; Guardant360 Response Test; Guardant360 TissueNext Test; GuardantINFINITY Test; GuardantConnect, an integrated software-based solution designed for clinical and biopharmaceutical customers to connect patients tested with assays with actionable alterations with potentially relevant clinical studies; GuardantOMNI Test for advanced stage cancer; and GuardantINFORM, an in-silico research platform for tumor evolution and treatment resistance across various biomarker-driven cancers.